Speaker

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service. Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology. In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China. Professor Lo was heavily involved in several committees of the HKSAR Government. He was the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau of HKSAR government from April 2015 to March 2021, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund of the HKSAR government. In Mainland China, Professor Lo was a member of the Chinese People’s Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the “Pericles International Prize” in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades. In the business sector, Professor Lo has served as the Chairman of Asia Pacific of PerkinEImer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited.

Dr. Hang Lu is the founder and CEO of NextTranslate Biopharmaceutical Co.，a clinical stage company focusing on the development and manufacture of mRNA- and advanced technology-based preventive and therapeutics products. 

Dr. Lu has over 25 years of experience in biological product development in pharmaceutical and biotechnology industry, including Merck Co. and Emergent BioSolutions (EBSI), a NYSE-listed global life sciences company that seeks to protect and enhance life by providing specialty products including vaccines and therapeutics for civilian and military populations. Dr. Lu held roles of increasing responsibilities at EBSI over the last 20+ years, including director of CDMO Analytical Development or PAD, Principal Scientist of R&D or Nonclinical Development. He was responsible for setting up the Immunotoxicology Lab and GxP Lab and was the core team member of more than ten traditional and new generation vaccines and biologics from the discovery to nonclinical and CMC development over the product life-cycle, from IND to BLA submissions leading to regulatory approvals in USA.

Dr. Lu obtained his medical degree at Zhejiang University and practiced as a pediatric hematologist，and then completed his post-doctoral research training at the University of British Columbia with a sponsorship from the Canadian Institutes of Health Research（CIHR）.

Dr. Lu is an advisory committee member of Vaccine Research Council，China Association for Vaccines and was the Presidents of the Chinese Biopharmaceutical Association (CBA，2021-2022) and CBA-China (2025-2027).

Lü Zhi has a long-term experience in cross-disciplinary researches on nature conservation and human sustainable development. She conducted field researches on the giant pandas and the snow leopard in western China and has expanded her work to promote biodiversity in cities and farmlands in recent years. She also deeply engaged in conservation practices especially community-based initiatives. For years she devoted to build a bridge between research and practice to better understand the interlinks between nature and people, and to provide empirical and practical solutions for their coexistence.

Professor Lyu Aiping is the Vice-President (Research and Development) and Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine at Hong Kong Baptist University. He was elected as a Foreign Member of the Academia Europaea in 2022, recognizing his sustained excellence in systems medicine. 

Professor Lyu’s research bridges Chinese Medicine and Western medicine through the lens of systems medicine, combining advanced techniques in life sciences and data sciences. He is interested in the novel re-classification of rheumatoid arthritis. His research has further delved into the dynamics of network biomarkers for re-classification and the interaction of combined drugs for precise treatment.

Before joining Hong Kong Baptist University, Professor Lyu was the Executive Director (Legal Representative) of the Institute of Basic Research in Clinical Medicine at the China Academy of Chinese Medical Sciences (CACMS). He has since been actively involved in standardization of Chinese Medicine and strategic planning on the Chinese Medicine development in China.

Professor Lyu’s contributions to academia are substantial, with 600 academic papers published in leading journals such as Nature Medicine, Nature Communications, and Briefings in Bioinformatics, covering a wide spectrum of integrative medicine. His research innovation has led to the award of more than 60 patents.

Prof. C.H. Eddie Ma focuses on developing cures for neurological diseases, including glaucoma, nerve injuries, traumatic brain injury, diabetics neuropathy, spinocerebellar ataxia, and Alzheimer’s Disease. His team advances neuroscience and regenerative medicine through multidisciplinary approach that combines drug repurposing, deep brain stimulation, cell and molecular biology, animal behavior, and genetics. He has published as corresponding author in top-tier journals such as Neuron, PNAS, Science Advances, Brain, Behavior, and Immunity, Journal of Clinical Investigation, and npj Regenerative Medicine. Over the years, he has delivered keynote speeches in several key international conferences.

Prof. Ma holds nine US/China patents and received Gold (2022) and Silver (2021) awards at the Invention Geneva Evaluation Days. Since joining CityUHK, he has secured HKD 43 million in external research funding such as RIF, GRF, ITF, HMRF, and NSFC. He founded AniTech HK Limited, which recently won both the “Winning Start-up” and “My Favourite Start-up” awards at HKTDC Start-up Express 2025. His company also received funding support from ITC’s TSSSU, CityUHK HK Tech 300 and Cyberport. Under his mentorship, many of his PhD students have progressed to faculty and pharmaceutical roles worldwide. 

He earned his BSc from HKUST, MPhil from HKU, and DPhil from Oxford. He received postdoctoral training at Harvard Medical School, Massachusetts General Hospital, and Boston Children’s Hospital.

Guanghui Ma is a professor of Institute of Process Engineering (IPE), CAS. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, Japan, respectively. She worked at Tokyo University of Agriculture and Technology (TUAT) as an assistant professor during 1994-2001. She joined IPE as a professor in 2001 and was promoted to the director in 2012. She has published over 500 papers, including Nature, Nat. Mater., Nat Nanotechnol., Nat. Biomed. Eng., Sci Transl Med., Cell Host & Microbe, Sci. Adv., Nat. Commun., JACS, Adv. Mater., edited several books such as “Microspheres and Microcapsules in Biotechnology”. She has more than 90 patents authorized, the technology and products have been commercialized in companies. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class; 2020) of the Chemical Industry and Engineering Society of China.

She was elected as the member of Chinese Academy of Sciences, the Fellow of TWAS, and the Fellow of American Institute of Medical and Biological Engineering (AIBME).

Ma Jie is the head of the National Center for Clinical Laboratories and the Biotherapy Center at Beijing Hospital, and a doctoral supervisor.

Professor Ma is one of the Beijing 100 Leading Talents in Science and Technology, one of the national candidates for the New Century Millions of Talents Project, a State Council Special Allowance expert, the chief expert of a state – key research and development project, the chief expert of a national science and technology major project, and an expert for the “12th Five-Year Major New Drug Creation” and “14th Five-Year Special Guidelines for Stem Cell and Tissue Repair”.

The tumor cell immunotherapy program developed by Professor Ma received two phase II clinical trial approvals from the State Food and Drug Administration in 2022. Currently, Professor Ma has carried out a number of phase I clinical research projects of tumor immunotherapy, and has won the First Prize of the Beijing Medical Science and Technology Award, the Third Prize of the Beijing Science and Technology Award, and the Second Prize of the China Medical Science and Technology Award, making important contributions to the promotion of tumor immunotherapy in China.

Professor Ma’s research interests include target screening and new technology development for tumor immunotherapy; Research and development of anti-tumor nanomedicine and new dosage forms modified by nanotechnology; Clinical application of tumor targeting therapy and immunotherapy, etc.

Robert Markelewicz, MD is the Chief Medical Officer of Abpro since 2018. Prior to that, he was Senior Medical Director at Celgene from 2014 to 2018, and Medical Director at Parexel from 2012 to 2014. Dr. Markelewicz received a Bachelors in Biology, a Masters in Medical Science and MD all from Brown University.

Dr. Angela Yuxin Men is the CMO of Haichang Biotech and the CEO of The WhiteOak Group. Prior to joining Haichang Biotech, she served as a master reviewer and team leader in the Clinical Pharmacology Office, CDER, FDA since 2003 with the responsibility of reviewing IND/NDA/BLA for oncology and neurological new drugs. ​She has received more than 50 awards from the FDA, including the Distinguished Service Award, Outstanding Mentor Award, Outstanding Leadership Award and Outstanding Regulatory Science Award, etc. She has actively organized and presented in various workshops and seminars at national and international conferences. In May 2022, Dr. Men was selected into the IFPMA ICH E21 expert working group. In addition, Dr. Men acted as a regulatory expert, providing reports and presentations to help resolve disputes in ICC arbitrations. She currently serves as President and board member of the Chinese Biopharmaceutical Association (CBA); general secretary, ex-Vice President and board member of the FDA Chinese Experts Club; Assistant Chair for the Membership and Community Outreach in the Federal Asian Pacific American Council (FAPAC) and a member of the China Pharmaceutical Innovation and Research Development Association. Dr. Men received her PhD in pharmaceutical sciences from Virginia Commonwealth University. Before that, she was a clinical neurologist with a medical degree from Tianjin Medical University.

Holly Meng serves as the Co-founder and Chief Executive Officer of EXIN BioPharma, bringing with her an extensive background of over three decades in business, industry, finance, international trade, higher education, and nonprofit operations. As a seasoned entrepreneur, she has successfully established and exited multiple businesses in her native Hong Kong and her current residence of 25 years in Philadelphia, Pennsylvania. In her capacity as a Senior Specialist of Business with SBA certification at the Fox School, Holly has provided invaluable guidance to more than 50 startups and small-to-medium enterprises (SMEs) in areas such as business planning and operations, funding and investment, marketing, business development, finance, and budgeting. Over the past decade, she has also made significant contributions as the Program Creator and Director of Temple Office of Executive Leadership Education, establishing extensive cross-border networking connections with over a thousand visiting executives, domestic leaders, and organizations on both national and global levels.

Holly has been an active volunteer in numerous nonprofit organizations, holding positions such as President of the American Center for Asian Students, Deputy Curator of the American Chinese Museum, and Vice President of Chinese BioPharmaceutical Association of Greater Philadelphia. In recognition of her exceptional achievements, she was awarded the U.S. President’s Lifetime Achievement Award in 2022. Currently, Holly is pursuing her doctorate in Higher Education Leadership and Policy.